Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
The durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-ter...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2424615 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184512640647168 |
|---|---|
| author | Michael Kwan Leung Yu Sophelia Hoi Shan Chan Daniel Leung Samuel Cheng Leo Chi Hang Tsang Tsz Chun Kwan Kaiyue Zhang Xiwei Wang Wenwei Tu Malik Peiris Yu Lung Lau Jaime S. Rosa Duque |
| author_facet | Michael Kwan Leung Yu Sophelia Hoi Shan Chan Daniel Leung Samuel Cheng Leo Chi Hang Tsang Tsz Chun Kwan Kaiyue Zhang Xiwei Wang Wenwei Tu Malik Peiris Yu Lung Lau Jaime S. Rosa Duque |
| author_sort | Michael Kwan Leung Yu |
| collection | DOAJ |
| description | The durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-term humoral immunogenicity outcomes after 3 doses of these vaccines. Peripheral blood samples were collected from participants 14–49 days and 155–210 days after administration of the third vaccine dose to assess humoral immune responses through serological assays. The immunogenicity outcomes of each patient were compared to those of three age-matched healthy control participants, ensuring a balanced comparison. Both patients that received 3 doses of BNT162b2 and 10 (90.9%) patients that received CoronaVac seroconverted against wild-type-SARS-CoV-2 virus, showing comparable antibody responses to healthy participants. After 6 months, one patient in BNT162b2 and all four patients in CoronaVac groups maintained seropositivity. The JN-1 specific binding antibody response was lower compared to wild-type virus. The use of corticosteroids did not affect seroconversion rate against wild-type virus or JN.1 variant. BNT162b2 and CoronaVac were immunogenic for neuromuscular diseases patients, maintaining durability after 6 months even for those on corticosteroids. Our data support a rapid immunization series utilizing mRNA-based and whole-virus inactivated vaccines for future pandemic. |
| format | Article |
| id | doaj-art-bafbe929cce940e8be1cef340211b5b5 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-bafbe929cce940e8be1cef340211b5b52025-08-20T02:17:01ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2424615Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patientsMichael Kwan Leung Yu0Sophelia Hoi Shan Chan1Daniel Leung2Samuel Cheng3Leo Chi Hang Tsang4Tsz Chun Kwan5Kaiyue Zhang6Xiwei Wang7Wenwei Tu8Malik Peiris9Yu Lung Lau10Jaime S. Rosa Duque11Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, ChinaThe durability of the immunogenicity elicited by three doses of mRNA-based BNT162b2 and whole-virus inactivated CoronaVac in patients with neuromuscular diseases, particularly those on immunosuppressive drugs and variants of concern, has not been well-established. Our goal was to evaluate medium-term humoral immunogenicity outcomes after 3 doses of these vaccines. Peripheral blood samples were collected from participants 14–49 days and 155–210 days after administration of the third vaccine dose to assess humoral immune responses through serological assays. The immunogenicity outcomes of each patient were compared to those of three age-matched healthy control participants, ensuring a balanced comparison. Both patients that received 3 doses of BNT162b2 and 10 (90.9%) patients that received CoronaVac seroconverted against wild-type-SARS-CoV-2 virus, showing comparable antibody responses to healthy participants. After 6 months, one patient in BNT162b2 and all four patients in CoronaVac groups maintained seropositivity. The JN-1 specific binding antibody response was lower compared to wild-type virus. The use of corticosteroids did not affect seroconversion rate against wild-type virus or JN.1 variant. BNT162b2 and CoronaVac were immunogenic for neuromuscular diseases patients, maintaining durability after 6 months even for those on corticosteroids. Our data support a rapid immunization series utilizing mRNA-based and whole-virus inactivated vaccines for future pandemic.https://www.tandfonline.com/doi/10.1080/21645515.2024.2424615BNT162b2COVID-19CoronaVacneuromuscular diseasesimmunogenicity |
| spellingShingle | Michael Kwan Leung Yu Sophelia Hoi Shan Chan Daniel Leung Samuel Cheng Leo Chi Hang Tsang Tsz Chun Kwan Kaiyue Zhang Xiwei Wang Wenwei Tu Malik Peiris Yu Lung Lau Jaime S. Rosa Duque Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients Human Vaccines & Immunotherapeutics BNT162b2 COVID-19 CoronaVac neuromuscular diseases immunogenicity |
| title | Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients |
| title_full | Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients |
| title_fullStr | Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients |
| title_full_unstemmed | Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients |
| title_short | Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients |
| title_sort | medium term immunogenicity of three doses of bnt162b2 and coronavac in hong kong neuromuscular disease patients |
| topic | BNT162b2 COVID-19 CoronaVac neuromuscular diseases immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2424615 |
| work_keys_str_mv | AT michaelkwanleungyu mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT sopheliahoishanchan mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT danielleung mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT samuelcheng mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT leochihangtsang mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT tszchunkwan mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT kaiyuezhang mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT xiweiwang mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT wenweitu mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT malikpeiris mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT yulunglau mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients AT jaimesrosaduque mediumtermimmunogenicityofthreedosesofbnt162b2andcoronavacinhongkongneuromusculardiseasepatients |